Jim,
I hear you about yahoo msg board, you and bitesr going back and forth.
The one reason of disappointment for me is I thought B-ABSSSI could
get a license deal done and get started. The Brilacidin 2B results were
impressive.
My only guess is BP don't want to do until halfway thru the Phase 3 and
seeing interim results.
Hopefully, a partner for Prurisol after 2B will get those funds for
B-ABSSSI. Can they run the required 2 B-ABSSSI Phase 3's
simultaneously....?? I hope so. From that point, an approved
B-ABSSSI would yield what?? - maybe a sale of this drug indication,
but at a discount due to the delay. Durata sold theirs for 675 million.
Trius (I think) think sold theirs for 717 million.
Understand how you feel.
I hear you about yahoo msg board, you and bitesr going back and forth.
The one reason of disappointment for me is I thought B-ABSSSI could
get a license deal done and get started. The Brilacidin 2B results were
impressive.
My only guess is BP don't want to do until halfway thru the Phase 3 and
seeing interim results.
Hopefully, a partner for Prurisol after 2B will get those funds for
B-ABSSSI. Can they run the required 2 B-ABSSSI Phase 3's
simultaneously....?? I hope so. From that point, an approved
B-ABSSSI would yield what?? - maybe a sale of this drug indication,
but at a discount due to the delay. Durata sold theirs for 675 million.
Trius (I think) think sold theirs for 717 million.
Understand how you feel.
